Rising to the ADC Challenge
The ADC market has continued to grow over the last decade – what advances should be embraced for true success?
Maryam Mahdi | | Interview
The antibody drug conjugate (ADC) market has faced its fair share of disappointments. But as the industry gets to grips with the underlying chemistry, progress is being made – evidenced by the growing number of approved drugs. Here, Lisa McDermott, Director of Process and Analytical Development at Merck, highlights the advances and technologies that will drive success in the ADC sector.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.